

# UCSF

## UC San Francisco Previously Published Works

### Title

First-in-human prediction of chronic pain state using intracranial neural biomarkers.

### Permalink

<https://escholarship.org/uc/item/3ck6m3jf>

### Journal

Nature neuroscience, 26(6)

### ISSN

1097-6256

### Authors

Shirvalkar, Prasad  
Proskey, Jordan  
Chin, Gregory  
[et al.](#)

### Publication Date

2023-06-01

### DOI

10.1038/s41593-023-01338-z

### Supplemental Material

<https://escholarship.org/uc/item/3ck6m3jf#supplemental>

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

# First-in-human prediction of chronic pain state using intracranial neural biomarkers

## Author List:

Prasad Shirvalkar M.D., Ph.D.<sup>1,2,3,5\*</sup>  
Jordan Prosky M.A.<sup>3,5</sup>  
Gregory Chin B.S.<sup>3</sup>  
Parima Ahmadipour B.S.<sup>7</sup>  
Omid G. Sani, Ph.D.<sup>7</sup>  
Maansi Desai M.A.<sup>6</sup>  
Ashlyn Schmitgen B.S.<sup>3,5</sup>  
Heather Dawes Ph.D.<sup>3,5</sup>  
Maryam M. Shanechi, Ph.D.<sup>7</sup>  
Philip A. Starr M.D., Ph.D.<sup>3,4,5</sup>  
Edward F. Chang M.D.<sup>3,4,5</sup>

## Affiliations:

Departments of:

- 1- University of California, San Francisco (UCSF),  
Dept of Anesthesiology and Perioperative Care,  
Division of Pain Medicine
- 2- UCSF Dept of Neurology
- 3- UCSF Dept of Neurological Surgery
- 4- UCSF Dept of Physiology
- 5- UCSF Weill Institute for Neurosciences
- 6- University of Texas at Austin, Dept of Speech,  
Language, and Hearing Sciences
- 7- University of Southern California – Dept of Electrical  
and Computer Engineering

\*Corresponding Author:

Prasad Shirvalkar

[Prasad.Shirvalkar@ucsf.edu](mailto:Prasad.Shirvalkar@ucsf.edu)

1651 4<sup>th</sup> Street, San Francisco CA 94158  
UCSF Medical Center

## Abstract

Chronic pain syndromes are often refractory to treatment and cause substantial suffering and disability. Pain severity is often measured through subjective report, while objective biomarkers that may guide diagnosis and treatment are lacking. Also, which brain activity underlies chronic pain on clinically relevant timescales, or how this relates to acute pain, remains unclear. Here, four participants with refractory neuropathic pain were implanted with chronic intracranial electrodes in the anterior cingulate (ACC) and orbitofrontal (OFC) cortex. Participants reported pain metrics coincident with ambulatory, direct neural recordings obtained multiple times daily over months. We successfully predicted intraindividual chronic pain severity scores from neural activity with high sensitivity using machine learning methods. Chronic pain decoding relied on sustained power changes from the OFC, which tended to differ from transient patterns of activity associated with acute, evoked pain states during a task. Thus, intracranial OFC signals can be used to predict spontaneous, chronic pain state in patients.

## Introduction

Chronic pain syndromes pose a major healthcare problem and are leading contributors to disability worldwide.<sup>1</sup> Neuropathic pain syndromes such as post-stroke and phantom limb pain are particularly refractory to treatment and impose substantial suffering. A hurdle to a mechanistic understanding of chronic pain, and the development of effective diagnostics and therapeutics, is the lack of objective measures of pain severity or underlying neurophysiology. Of necessity, chronic pain is commonly measured by the patient's subjective report, an interrogative approach limited by difficulties in quantitation, reliability, and inter-participant comparability. Objective biomarkers for chronic pain would greatly facilitate diagnosis and classification of pain pathophysiology, assist with disease prognostication or prediction of therapy response, and catalyze therapeutic development.<sup>2,3</sup>

Most prior attempts to identify pain biomarkers have focused on healthy participants and experimental thermal pain, which ignores natural, spontaneous fluctuations in patients' chronic pain experience.<sup>4-7</sup> Even studies of spontaneous chronic pain severity are limited by characterization over short time scales (minutes) due to reliance on *ex vivo* technology such as electroencephalography<sup>7</sup> or blood-oxygen-level-dependent functional MRI (BOLD-fMRI)<sup>8,9</sup> that are not amenable to frequent, long-term measurement. Further, interpretation of BOLD-fMRI responses associated with chronic back pain is complicated due to inclusion of patients with heterogeneous sources of pain (e.g., inflammatory, myofascial, neuropathic). It is unclear whether lessons learned from healthy human participants or mixed pain syndromes translate to patients with chronic neuropathic pain over clinically relevant time periods. A growing body of evidence from humans and animals suggests that chronic pain processing engages the medial frontal cortex in a manner distinct from acute, thermal pain<sup>10-13</sup>.

Frontal brain regions harbor important signals that integrate the somatosensory, affective, and cognitive dimensions of pain. The rostral anterior cingulate cortex (ACC) has been extensively implicated in affective / emotional processing related to both acute and chronic pain<sup>10,14</sup> and proposed as a therapeutic stimulation target to treat chronic pain.<sup>15</sup> The orbitofrontal cortex (OFC) has rarely been studied in pain, but its reciprocal connections with ACC and many other regions in the functional pain network such as

amygdala, insula and ventral striatum<sup>16,17</sup> make it well positioned to influence pain perception. Functional imaging has revealed increased OFC activity in response to multimodal sensory stimuli, during tasks requiring the integration of bodily signals to guide behavior (e.g. interoception)<sup>18,19</sup>, reversal learning, and pain expectation related to monetary reward<sup>20</sup>. Direct recordings from OFC have confirmed key signals that track internal deliberation of reward choices<sup>21</sup> and OFC stimulation can improve mood state in depressed patients<sup>22</sup>. Other studies have identified the ventromedial prefrontal cortex, a region overlapping with definitions of OFC, as an important region associated with interindividual variability in acute pain perception<sup>23</sup> and negative affective responses to multimodal stimuli<sup>24</sup>. Specific coactivation of the dorsal ACC and OFC is seen both during opioid consumption and in response to placebo analgesia,<sup>25</sup> implicating these regions in myriad functions ranging from sensory perception, expectation, cognitive flexibility and mood regulation. While long distance connections between ACC/OFC and subcortical structures may support plasticity underlying chronic pain, signals from either brain region alone may be sufficient to track pain state. It remains an open question whether previous studies of chronic back pain due to heterogeneous pain generators generalize to true neuropathic pain states or is reflected in direct brain activity *in vivo*. Therefore, we targeted two relatively less-studied, non-somatosensory brain regions as part of a larger deep brain stimulation clinical trial. We hypothesized that neural activity from ACC or OFC may provide an integrated biomarker of the subjective experience underlying chronic pain severity. To our knowledge, long-term direct brain measurement of chronic pain-related neural activity has never been done.


By studying brain biomarkers with high resolution across both short (sub-second) and long timescales (months) in humans, we aimed to develop a sensitive test of high pain states and study the neurophysiologic basis of spontaneous chronic pain. Such insights potentially bring new clarity to pain biology and help to inform personalized treatments such as tailored closed-loop deep brain stimulation (DBS) therapies for chronic pain.<sup>26,27</sup> We collected pain reports and intracranial recordings in the ambulatory setting using a novel bidirectional brain implant (Medtronic Activa PC+S) in four human participants with long-standing refractory, chronic neuropathic pain over 3-6 months. These are first-in-human chronic *in vivo* neural recordings of key

pain related cortical regions,<sup>8,14</sup> ACC and OFC. We analyzed local field potentials (LFP) with machine learning to develop personalized neural signatures for chronic pain severity and characterize the relative feature importance from each brain region. By comparing brain-based signatures for spontaneous, chronic pain with signatures derived for acute, evoked thermal pain, we identify distinct neural substrates for each. Brain biomarkers of chronic pain reflected sustained changes in neural power features that tended to rely more on OFC, which only generalized to the acute pain condition within one participant. Acute pain decoding tended to reflect greater contributions from ACC with more frequent and transient changes in power. Biomarker decoding was superior for current vs recent changes in pain state and largely stable over time. These data provide the first demonstration that spontaneous, chronic pain states can be predicted from direct brain activity over ecological timescales in the ambulatory setting.

## Results

### Longitudinal Pain-State Tracking

Each participant provided pain score reports multiple times daily (range 2-8/day) over a range of 78-184 days (mean 320 reports/participant, **Table S1**). All participants reported 11-point pain intensity NRS (0-10) while two participants (CP3,CP4) also provided pain intensity visual analog score (VAS), the short-form McGill Pain Questionnaire (SF-MPQ), and pain unpleasantness (NRS and VAS). Pain NRS values were high for all participants (mean  $\pm$ SD 7.8  $\pm$ 0.9) and all ratings exhibited fluctuation exceeding established minimal clinically important differences (MCID for SF-MPQ  $>5$ <sup>28</sup>, NRS $>2$ <sup>29</sup>, VAS $>1.6$ , **Figure 1B,C**). To assess internal validity of pain score reporting, we computed Pearson's correlations between VAS and NRS for pain intensity and unpleasantness, which were highly correlated within-participant (**Figure 1D**,  $R^2$  range = 0.84-0.96). We evaluated periodicity in chronic pain fluctuation by computing an autocorrelation for each participant's pain NRS (**Figure 1E**). While all participants showed diurnal cycles in their pain states, we also observed clinically significant multidiurnal cycles of pain fluctuation, with two participants exhibiting pain fluctuation nearly every 3 days (72h, CP1 and CP3).



**Figure 1 - Long Term Ambulatory Tracking of Chronic Pain Metrics**

**a**, Self-drawn body maps corresponding to the anatomical distribution of each of four participants' spontaneous chronic pain location. Red and blue indicate areas of high and low pain, respectively. **b**, Scatterplot of an example participant's report of overall pain intensity VASs over 105 d (mean 3.2 reports/d), with overlying moving average (red line; window = 3 samples), demonstrating a range larger than MCID. Each black point represents one pain report simultaneous with a neural recording. **c**, Histogram of each participant's reported pain intensity NRS; most values were high (>6/10) but similar across participants. **d**, Group data demonstrating high correlation between VAS and NRS for pain intensity and unpleasantness across participants who reported them (CP3–4) with associated Pearson's correlation  $R$ . **e**, Partial autocorrelation stem plots for each participant's pain NRSs. Different pain score reporting frequencies for each participant resulted in different autocorrelation resolution. Bold stems indicate time lags achieving statistical significance ( $P < 0.05$ ) based on two-sided 95% confidence intervals (for CP1–4, respectively:  $\pm 0.12$ ,  $0.14$ ,  $0.13$  and  $0.09$ ) not corrected for multiple comparisons.

### Cross-Validated Decoding of Chronic Pain State

To identify biomarkers of chronic pain state, we used ambulatory, intracranial local field potential (LFP) recordings from ACC and OFC (**Figure 2A, B**) to build models decoding each participant's pain severity scores. Candidate biomarkers consisted of spectral power in frequency bands of interest, which showed no clear trend over time to suggest non-neural changes in recordings (**Figure S1**). We first tried predicting exact reported pain metrics using cross-validated multivariate LASSO regression on neural band-power data (**Figure S3**). First, we created *subregion decoding models* using band-power values sub-selected from individual brain regions and/or hemispheres and *full models* using all available data (i.e., bilateral ACC/OFC **Figure 2C, D**). For participants with bihemispheric electrode implants (CP2-4), there were 9 possible subregion models through possible combinations of contralateral, ipsilateral, or both hemispheres (relative to side of pain) from either the ACC, OFC, or both regions. Overall regression-based prediction showed mixed results (**Figure S3**), often poor but at other times comparable to classification (below). Regression of NRS pain intensity was poor in all participants with multivariate coefficients of determination ( $R^2$ ) between observed vs predicted scores ranging from -0.2 to 0.1 across all *subregion* and *full models*. LASSO regression performance on the alternative metrics of pain intensity VAS and unpleasantness NRS in two participants showed  $R^2$  values as high as 0.3 (CP4 UNPNRS). Even an  $R^2$  value of 0.18 (CP3 VAS) is equivalent to a Pearson's  $r = 0.42$ , a moderate effect size which corresponds a binary classification  $AUC = 0.74$  assuming normally distributed, equal samples<sup>30</sup>. Notably, regression performed well when predicting MPQ in two participants, as evidenced by many  $R^2 > 0.7$  (CP4). In summary, regression models performed moderately at best, when predicting pain intensity (NRS or VAS), but fared better for other pain metrics. Specifically for tracking pain intensity, these results may further support prior observations that a forced-choice between low versus high pain states may be more pragmatic for clinical application<sup>6</sup>.

To investigate the role of different cortical circuits in a forced-choice framework, we turned our attention to predicting dichotomized pain scores (high vs low divided by median). Using cross-validated LDA (see Methods) with at least one *subregion model*, dichotomized chronic pain NRS could be classified in all participants (**Figure 2D, E**, highest LDA AUCs (p-value) and **Figure S4**): 0.673 (0.016), 0.851 (0.001), 0.721 (0.001), 0.802 (0.001)

for CP1-CP4 respectively. Ranges for chronic pain NRS decoding statistics were as follows: positive predictive value (PPV) 0.83-0.93, sensitivity 0.62-0.84, and specificity 0.56-0.82 (**Table S2**). In 3 participants, the best decoding performance resulted from either *full models* or combining ACC and OFC activity in either hemisphere. Overall, chronic pain state could be significantly decoded across all patients using contralateral OFC alone. Misclassified pain states were distributed across timepoints spanning months and the range of pain scores (i.e., not only near the dichotomized boundary), confirming robustness of prediction (**Figure S5**). Decoding and biomarkers appeared stable over time. Compared to the LOOCV method (which leaves out power values and pain score class associated with one recording clip at a time) we observed better performance when we trained LDA pain NRS models on the first 70% of data and tested on the remaining 30% with AUCs near 0.9 in all but in one participant (CP1), with fewest number of recordings (**Figure S6**). This suggests stability in the biomarkers tracking pain intensity NRS over the timescale of months.

To test performance of an independent method (LSSM) that may be used to flexibly guide brain stimulation, we used *full models* (**Figure S7**) to predict pain intensity NRS. LSSM had similar performance to LDA in all participants except CP1. Moreover, two participants reported additional pain metrics including pain intensity VAS, pain unpleasantness NRS/VAS and SF-MPQ. *Full models* could significantly decode these pain metrics using both LDA and LSSM (**Figures S7, S8, S4, S5A**) except for CP3 unpleasantness-VAS using LSSM. Using LDA, SF-MPQ decoding showed equally high performance using either the *full model* or contralateral OFC/ACC *subregion model* (AUC (p-value) CP3 = 0.623 (0.004); CP4 = 0.995 (0.001)), with PPV ranging from 0.77 – 0.99 (**Table S2**). Further, using single region *LDA models* for classification of chronic pain unpleasantness NRS, a measure of the affective dimension of pain, showed the highest AUCs for data from contralateral ACC (AUC 0.69 (CP3) and 0.84 (CP4)) as expected.

By visualizing the normalized, mean LDA feature weights supporting successful LDA decoding (**Figure 2E**), we observed that the most important power features varied across participants. Despite this variability, a single brain region was sufficient to track chronic pain states in each participant, with contralateral OFC being common across all participants.



It is possible that neural features may track the relative fluctuation of pain, rather than the current pain state. To test for this possibility, we constructed regression and LDA models of successive pain score differences (i.e., prior pain score subtracted from current pain score **Figures S9a, S9b**). Dichotomizing these difference values by those equal to zero (no change) vs those that were non-zero (increasing or decreasing) may identify neural activity distinguishing stable vs fluctuating pain states. Classification of stable vs fluctuating pain NRS was broadly significant only in one participant (CP4). Consistent with prior results<sup>8</sup>, we observed that stable vs changing pain scores in two participants (CP2,3) could be distinguished only when models included neural signals from ACC. All LDA model AUCs were inferior to contemporaneous pain *state* prediction (**Figure S9a**). Further, regression of pain NRS difference was poor across

participants ( $R^2$  range -0.2 to 0.1) and alternative pain metric regression (e.g., VAS) was not successful except for unpleasantness NRS and VAS each one participant (**Figure S9b**). The failure of regression to robustly predict increases or decreases in sequential pain scores over many hours may imply that ACC or OFC harbor weak signals for prediction errors over these timescales or that subjective pain experience is integrated over shorter historical durations than many hours. Therefore, while LFP from ACC and OFC may contain information relevant to recent changes in pain, the current chronic pain experience appears to be more reliably represented across participants and pain related metrics compared to pain fluctuations.



### Figure 2 - Ambulatory Neural Recordings From ACC And OFC Predict Chronic Pain State

**a**, Example X-ray of a participant with bilateral implant of Activa PC + S DBS generators attached to depth leads in the ACC and paddle leads in the OFC (red highlights). **b**, Group localization of all electrode contacts in coronal (top) and sagittal (bottom) view. Blue shaded area is the ACC; yellow shaded area is OFC. Below are example raw LFP recordings from ACC (top) and OFC (bottom). **c**, Summary of the chronic pain-state decoding scheme for pain VAS using example data from one participant. Normalized power spectra are computed for each recording (ordered by increasing pain VAS (overlaid white circles) for display) and power values at each frequency are displayed across all recordings for an example participant. Above the color bar scale, a horizontal histogram of pain VAS shows the distribution of pain scores, which are split by the median value to define a dichotomous response variable (high (1) versus low (0) pain states). Average power values in frequency bands of interest serve as predictive features in two complementary decoding schemes. Power features sub-selected from either brain region or hemisphere are used to train models that decode high versus low pain states using LDA. **d**, Bar plots of decoding performance with successful pain-state prediction based on NRS for all participants using LDA. CP1–CP4 had  $n = 89, 137, 234$  and  $452$  independent simultaneous recordings and pain score reports, respectively. One-sided empirical  $P$  values were calculated using permutation tests ( $n = 1,000$ ; black dots), without correction for multiple comparisons ( ) as reported in Supplementary Fig. 4 for all metrics and models.  $P$  values for NRS models in **d** from left to right are: CP1: 0.092, 0.801, 0.016; CP2: 0.001, 0.001, 0.001, 0.001, 0.001, 0.002, 0.001, 0.003, 0.777; CP3: 0.001, 0.005, 0.041, 0.001, 0.002, 0.027, 0.001, 0.001, 0.143; CP4: 0.001, 0.001, 0.001, 0.001, 0.001, 0.001, 0.001, 0.612, 0.001. **e**, Normalized mean feature weights (importance) for each participant from full models (bilateral OFC/ACC) in **d**. (Note CP1 only has a unilateral implant. Contra, brain hemisphere contralateral to participants' body side with chronic pain; ipsi, ipsilateral.  $\ddagger P < 0.05$ ,  $*P < 0.01$ ,  $\dagger P < 0.001$ ).





**D LDA Classification (Chronic Pain NRS)**






### Cross-Validated Decoding of Acute Pain State

To compare with neural mechanisms supporting chronic pain, we next sought to identify biomarkers of acute, experimental thermal pain state. Brain recordings and pain ratings were collected while participants participated in quantitative sensory testing (QST, **Figure 3A**). Background chronic pain ratings just before the acute task were equivalent to the mode of patients' reported scores (participants CP1-4, NRS, 9, 8, 7 and 8/10, respectively - compare to **Table S1**). Heat stimuli at five different temperatures, calibrated for each participant, were applied with a thermal probe to the most painful region on the side of the body affected by chronic pain (aff-ACUTE) and the same body part on the unaffected side (unaff-ACUTE) for up to six trials per target temperature; pain intensity NRS was reported 3 seconds after target temperature was reached (**Figure 3B-D**). Participants were extensively trained on the task to avoid potential reporting confounds with respect to usual chronic pain (see Online Methods). *Subregion LDA models* demonstrated significant prediction of high vs low acute pain in the aff-ACUTE condition in two participants, only when trained on data including ACC (CP1  $AUC_{LDA} = 0.738$ ,  $p = 0.045$ ; CP2,  $AUC_{LDA} = 0.74$ ,  $p = 0.037$ , **Figures 3E, S10**). Given unsuccessful decoding from any models trained on OFC alone, these data may suggest preferential involvement of ACC in circuits harboring acute pain signals. Tested models could not significantly predict acute pain in the unaff-ACUTE condition (**Figure 3F**). In contrast to acute pain metrics on the affected side, we found no significant decoding of the actual delivered temperature on the affected side in any participant (**Figure S11**). One participant (CP4) showed significant decoding of temperature when applied to the unaffected side.

Again, key neural features supporting acute pain state prediction varied between the two participants in which decoding was possible, with the highest magnitude feature weight coming from ACC for each (CP1 contra ACC alpha, CP2 contra ACC beta, **Figure 3G**). Notably, features supporting acute pain decoding visually differed from those supporting chronic pain (compare to **Figure 2E**). If neural features that drive decoding of chronic pain state are similarly important for supporting acute pain decoding, *full LDA models* trained on the former should perform well when tested on data from the latter. We only observed such generalization from chronic to acute pain in one participant (CP2) who did not have a preexisting brain lesion (**Figure S12**). The lack of such generalization between acute and


chronic pain representation in the remaining three participants suggests distinct neural codes in ACC and OFC in these participants.



## ACC and OFC Distinguish Acute and Chronic Pain States

The extent to which neural representations of chronic pain and acute pain states resemble one another is a major gap in knowledge. One way to gain additional insight into associated neurophysiological mechanisms underlying chronic vs acute pain is to compare the importance of neural features driving prediction of each pain type. We assessed the relative importance of OFC vs ACC by subtracting each normalized ACC feature weight from the corresponding normalized OFC feature weight to obtain a distribution of feature importance differences; this difference distribution was then compared to a permuted, null distribution to assess if activity from OFC or ACC was more important to pain decoding than by chance (see LDA Feature Importance in Methods, **Figure 4A,B**). Values greater than 0 indicate greater OFC importance. We

observed that the OFC was more important than ACC to chronic pain NRS decoding in a greater proportion of all features for 3 participants (OFC proportion of significant features: CP1=100%, CP3=75%, CP4= 58%). Common for all participants, contralateral OFC delta power was consistently more important than contralateral ACC delta to decoding chronic pain NRS (Wilcoxon rank sum Z range = 13 - 36.3,  $p = 10^{-6}$ ). In contrast, for acute pain decoding in two participants, ACC appeared more important than OFC for a greater proportion of all significant features when compared to chronic pain (**Figure 4B**, acute vs chronic pain ACC proportion: CP1 100% vs 0%, CP2=64% vs 58%). Because feature importance for acute pain was only assessed in two participants showing successful acute pain decoding, caution is advised in interpretation due to low participant numbers.



**Figure 4 - Decoding of chronic and acute pain states are differentially supported by OFC and ACC features across participants**

Panel A shows relative importance of OFC vs ACC normalized power features to decoding of chronic pain NRS *full models* in each participant. Individual histograms show distributions of the magnitudes of OFC feature weights minus ACC feature weights across all recording sessions for real data (black, left facing) and shuffled surrogate data (grey, right facing, see Online Methods). Values above 0 indicate greater OFC weights, and below 0 indicate greater ACC weights. Contralateral OFC delta power was more important than ACC for discriminating high vs low pain across all participants (red highlight). Panel B similarly shows relative feature importance for Acute-affected pain for the two participants that had significant decoding. Note that for acute pain, there is shift to greater ACC importance across frequencies compared to chronic pain (Two-sided Wilcoxon rank-sum test, p-values corrected for multiple comparisons with Benjamini-Hochberg method Panel A: \*all  $p < 10^{-4}$  except CP1†  $p = 0.002$ , CP2†  $p = 0.043$ , CP3†  $p = 0.001$ . Panel B: \*all  $p < 10^{-3}$ , except CP1†  $p = 0.046$ , CP2†  $p = 0.042$ .)

## Neural Time Dynamics Distinguish Acute and Chronic Pain


We next sought to characterize the temporal dynamics of these power bands by analyzing patterns of power changes at short-term (seconds, within a recording) and long-term scales (diurnal, across recordings). Chronic and acute pain decoding model features consisted of band-passed power, time-averaged over the duration of the recording clip (30s for chronic, 3s for acute), which variably showed increases or decreases associated with predicting a “high pain” state (**Figure 2E, 3G**).

It is possible that if a feature was important to “high pain” decoding, power changes may be associated with either transient or sustained changes within specific frequency bands over time or some combination of the two. To distinguish these possibilities, we calculated the power timeseries of each feature over the duration of the recording clip and averaged among clips in the high vs low pain groups (**Figure 5A, S13**). This analysis gives an impression of how average power associated with high or low pain fluctuates in real time. As expected, we observed that if a feature weight was positive or negative (**Figures 2E, 3G**), then that feature’s average power was respectively increased or decreased over time during high pain states, compared to low pain states (**Figure 5A, S13**). For example, a negative signed feature weight for contralateral OFC delta indicates that the contralateral OFC delta power was concordantly decreased during high pain states. Across each 30s recording clip for chronic pain decoding, the total power amplitude maintained this concordant relationship 76% of the time (group mean  $\pm$  std =  $22.8 \pm 6.2$ s, **Figure 5B**) across all participants. Although we observed fluctuations in the power values over the 30s duration, the top 5 power features were associated with sustained changes lasting a mean of 4.4 seconds ( $\pm 8.8$  std) above or below the low pain state average. We rarely observed transient bouts of fluctuation among chronic pain features, suggesting that temporal dynamics in decoding features reflected sustained oscillations relevant to ongoing perceived pain.

Despite a shorter 3 second recording clip duration for acute pain trials, we observed that power increases and decreases occupied a similar total proportion of recording clip time for both acute and chronic pain features (76.4% of total time acute vs 76% chronic; acute group mean  $\pm$  std =  $2.1$ s  $\pm$   $0.3$ s, rank sum  $p > 0.08$ , **Figure 5B**). In contrast to

chronic pain, however, the top 5 acute pain features showed more temporal variability with more transient bouts of fluctuation lasting an average of 0.56 seconds (SD = 0.18s, rank sum  $p < 10^{-14}$ , **Figure 5C**). Notably, we rarely observed such bouts of increases or decreases approaching 3 seconds, which was the theoretical upper limit given acute recording duration of 3s. Since these bouts of power increases or decreases occurred for a similar proportion of recording clip duration for chronic and acute pain data, we expected that the more transient bouts would occur more frequently for acute pain features. As expected, acute pain features showed many more frequent bouts of increases or decreases compared to chronic pain features (acute =  $1.3 \pm 0.29$  bouts per sec vs chronic =  $0.23 \pm 0.18$ , rank sum  $p < 10^{-19}$ , **Figure 5D**). Therefore, compared to chronic pain, the top 5 acute “high pain” biomarkers exhibited shorter, more frequent bursts of power changes, resulting in a similar total percentage of time with increases or decreases between high and low pain states.

To characterize longer scale time dynamics of chronic pain neural features, we performed a diurnal analysis by organizing both pain scores and neural features by time-of-day of report and resampling this diurnal pattern at 3-hour time resolution to model diurnal fluctuations (see Online methods, **Figure S14, Table S3**). We did not observe significant correlations between the diurnal trends of neural features and of pain NRS for any feature, in any participant. Overall, chronic pain decoding was associated with sustained power changes over time, distinct from more transient bursts of power changes supporting acute pain decoding. Diurnal time dynamics of neural features did not appear grossly related to diurnal fluctuations in pain metrics, suggesting a possible importance for short time scales in encoding subjective pain states.



**Figure 5 - Temporal dynamics of power features distinguish chronic from acute pain states**

Panel A shows an example power time series plot of a single feature (contralateral OFC delta) averaged across all recordings from low (blue line) vs high pain state (red line), for one participant. Colored and shaded error bars show s.e.m. The blue square in the upper left corner represents that feature's average weight as plotted in **Figure 2E** (blue = negative weight  $\sim -1.0$ ). This negative feature weight corresponds to decreased mean power during high pain states; periods of decreased power are highlighted with background grey shading. Panel B shows boxplots with overlying raw data of the percentage of total recording clip time on which increases or decreases occurred for chronic pain features (black dots) and acute pain features (red dots). Panel C shows the mean duration of bouts of increases and decreases similarly. Panel D shows the number of increases or decreases per second for chronic and acute pain features; symbol legend in panel D applies to panels B-D. In panels B-D for CP1-4 chronic pain features, respectively,  $n = 215, 455, 880$  and  $1765$  independent power timeseries. For CP1 and CP2 acute pain features, respectively,  $n = 35$  and  $60$  independent power timeseries. Box plot bounds indicate 25<sup>th</sup> and 75<sup>th</sup> percentiles, pink line shows median, and whiskers show full extent of data from minima to maxima with points outside the whiskers considered outliers. (\*two-sided Wilcoxon rank sum tests with correction for multiple comparisons) Panel C,  $Z_{CP1} = 7.7$   $p = 10^{-14}$ ,  $Z_{CP2} = 11.6$ ,  $p = 10^{-30}$  and \*Panel D,  $Z_{CP1} = -8.9$   $p = 10^{-19}$ ,  $Z_{CP2} = -12.5$ ,  $p = 10^{-35}$ . (See **Figure S13** for additional details and top 5 features per participant).

## Discussion

Objective biomarkers of spontaneous chronic pain severity are requisite for understanding basic mechanisms of clinically relevant pain, diagnosing pain syndromes, prognosticating disease course, and devising new therapies. Using first-in-human long-term, ambulatory, intracranial recordings in four participants with chronic, neuropathic pain, we used LFP signals from ACC and OFC to predict various measures of chronic pain severity, with high sensitivity. While we could predict dichotomized pain state using two different methods, regardless of pain etiology, duration of symptoms, or nervous system lesion, prediction of continuous metrics using regression was not as successful. Chronic pain biomarkers appeared stable over months in three of four participants and were more predictive of current pain state rather than recent transitions in pain report. In two participants, we could also predict acute, evoked thermal pain during an experimental heat pain task. We observed that chronic pain decoding tended to rely more on activity in the OFC (e.g., contralateral OFC delta) as evidenced by OFC subregion models and greater OFC feature weights across participants. Acute pain decoding was supported more by ACC activity. Finally, the time course of neural activity supporting chronic pain decoding reflected sustained increases or decreases in power on the order of seconds, while acute pain decoding was associated with more frequent transient changes in power. These results provide a proof of principle that signals from key neural hubs can be used to track clinically relevant chronic pain states in humans and have important implications for understanding circuit mechanisms underlying the chronification of pain.

While a complex neural network underlies the maintenance of chronic pain states<sup>17,31</sup>, we found that activity from either ACC or OFC alone was sufficient to track pathological network activity underlying chronic pain fluctuation. Previous neuroimaging studies of chronic back pain established the importance of the ACC and medial prefrontal cortex,<sup>32,33</sup> though notably failed to identify a role for OFC, possibly due to sparse time resolution of up to 4 visits over 1 year. Consistent with prior studies of spontaneous, chronic back pain measured over seconds to minutes in a single visit, we observed that ACC activity in three participants could discriminate when spontaneous pain was stable vs fluctuating.<sup>8,12</sup> The present findings suggest that signals in OFC can track current chronic pain severity for neuropathic pain

syndromes such as central post-stroke pain (CPSP) or phantom limb pain. In the context of prior studies supporting a broad role of the OFC in reward, punishment and placebo effect<sup>18,25</sup>, OFC circuits may integrate pain expectation and context-dependent predictions that influence subjective pain evaluation which may include rumination or engagement of coping mechanisms. Areas we indicate as OFC in this study also overlap with prior definitions of VMPFC, which has been associated with interindividual variability in pain perception and aversiveness<sup>23,24</sup>. In two participants with CPSP, decoding of pain unpleasantness was driven more by ACC activity, also consistent with prior roles of ACC circuits in affective<sup>14,34</sup> dimensions of pain processing. However, the preferential importance of ACC in acute pain decoding (which is described as having a smaller affective component than chronic pain states) challenges prior concepts of a medial pain pathway<sup>35</sup> from the medial thalamus to ACC as selective for affective processing<sup>11</sup>.

In contrast to the spontaneous and enduring phenomenology of chronic pain, acute thermal pain administered to patients reflects a transient, externally evoked pain experience. In two participants, acute, evoked pain was associated with distinct spatiotemporal activation patterns consisting of transient power fluctuations biased toward ACC. This observation is consistent with numerous imaging studies showing ACC as a key node activated with experimental pain stimuli across individuals.<sup>4,6,12,23,36</sup> Transient bursts of power among cingulate neurons may reflect facilitation of nociceptive hypersensitivity by recruitment of descending serotonergic projections to the spinal cord<sup>11</sup> or ascending information flow from the medial thalamus<sup>37</sup>. Though most participants exhibited thermal allodynia, the transient power change patterns underlying acute pain decoding in the current study were found in two participants (both women): one with severe allodynia and hyperpathia (CP1) and one with a normal neurological sensory exam (CP2), which may suggest preserved information processing mechanisms across disparate phenotypes. However, within-participant generalization of chronic to acute pain biomarkers was only found in one participant with phantom pain (CP2), without an ischemic brain lesion, suggesting that more robust models that directly incorporate acute vs chronic pain classes may potentially aid in discriminating pain syndrome subtypes or reflect cortical reorganization after a lesion.<sup>33</sup> As acute, evoked pain was only decodable when the painful stimulus was applied to the same body side as



ongoing chronic pain, the absence of evidence of successful decoding should not be interpreted as evidence of absence, possibly due to sample size of participants, trial number or environmental context (e.g. at home vs in clinic testing).

Global cerebral pain networks in all participants likely underwent rewiring over many years living with chronic pain<sup>32</sup>. Still, ongoing 'background' chronic pain may have influenced acute pain perception even in the unaffected body side (but see Methods for testing precautions used). Rather, the inability to decode acute pain in the unaffected side may suggest that ACC and OFC are either sensitive to pain on one side of the body or perhaps more sensitive to representing pain in body regions where chronic pain is ongoing. It is possible that an acute pain signal may be detectable in OFC if a task explicitly requires decision making or pain anticipation components as seen in prior studies<sup>38</sup>. If the contributions of ascending vs descending pathways to acute vs chronic pain processing can be elucidated in future studies, this would help to explain the common clinical observation that the chronic pain experience is not simply a more enduring version of acute pain.

Classical models of the role of neural oscillations propose that frequency-specific activity serves to flexibly route information flow through networks to support selective attention<sup>39</sup> and working memory<sup>40</sup>. Oscillations within a particular brain region may represent modulation of postsynaptic excitability, which itself impacts input gain<sup>39</sup>. The present observation that chronic pain intensity was associated with sustained increases or decreases in OFC power may therefore reflect maladaptive plasticity or changes in excitation/inhibition<sup>41</sup> between OFC and afferent primary sensory cortices, magnocellular cells of the medial thalamus or reciprocal connections with the ACC<sup>18</sup> to perpetuate pathological sensory integration. In contrast, transient burst-like oscillatory activity associated with acute pain intensity may reflect stochastic packets reflecting fast computations<sup>42</sup> between ascending medial thalamic inputs or descending rostral brainstem outputs supporting allodynia or evoked pain. Similar transient 'high current spikes' in rodent ACC have been observed to shift to more transient states in response acute noxious stimuli, and more sustained spiking states in a rodent model of post-stroke pain<sup>37</sup>. We further speculate that transient burst-like power changes may support aberrant sensory, affective and cognitive integration in chronic pain in

a manner analogous to how pathological beta bursting influences motor processing in Parkinson's Disease.<sup>43</sup> Of note, because our decoder inputs consisted of time-averaged power values, it is unlikely that these disparate temporal dynamics were responsible for the lack of generalization between acute and chronic pain we observed here.

Though we could reliably predict multiple metrics of chronic pain severity when scores were dichotomized into 'high' and 'low' categories, prediction of exact pain scores with linear regression fared relatively poorer for metrics tracking pain intensity. One reason for this may be that subjective pain perception is psychophysically nonlinear<sup>44</sup>, in a manner that binarization may better capture<sup>45</sup>. Binary classification yielded high sensitivities across patients which is crucial for practical diagnostic or therapeutic biomarkers. Consistent with prior suggestions<sup>3</sup>, such a binary biomarker could be more useful for diagnosis or disease classification, while continuous measures or grading scales may be more useful for assessing treatment response. Future analysis of neural signatures that predict treatment response would lend further insights to basic pain mechanisms.

Three of four participants suffered from CPSP, due to ischemic brain injuries acquired greater than two years before data collection. Despite potential concern that a previous stroke may have induced brain plasticity specifically related to stroke symptoms, all participants had stable symptoms and physical exams over the study period. While OFC activity was sufficient to decode chronic pain in these participants despite varying locations of ischemic infarcts or stable use of various pain medications, in many cases activity from ACC also performed as well. Given the small sample size of the present study, and idiosyncratic decoding observations in acute pain from 1-2 patients, caution must be used to avoid overinterpretation. Further studies are required to establish greater confidence in the specificity of OFC for chronic pain prediction across larger groups.

A further limitation of the current study is that rather than directly predicting pain state per se, it is possible that machine learning models may be predicting other variables strongly correlated with reported pain metrics such as arousal or attention. However, as the adaptive value of pain may be to alert the organism to impending tissue damage, arousal effects may be a fundamental component of the complex subjective perception of pain itself. Further, in the diurnal analyses, we found many non-

significant correlation values with large effect size ( $r > 0.5$ ). Because we did not explicitly quantify Bayes' factors related to the null hypothesis, the absence of evidence should not be interpreted as evidence of absence for a particular effect, particularly in cases of non-significant model results where the effect size may be high.

The development of personalized pain biomarkers will be central to accurate diagnosis, tracking prognosis and for future therapeutic drug and device development. Individualized biomarkers are also critical to the growing field of adaptive neurostimulation, where a patient's ongoing neural activity may be used to control therapeutic brain stimulation<sup>46</sup>. Personalized biomarkers of chronic pain state may be used as input signals in real-time, to control the amplitude or frequency of therapeutic electrical brain stimulation for treating refractory pain as they have for movement disorders. By adaptively delivering intermittent bouts of stimulation or adjusting parameters based on pain-state biomarkers, it may be possible to mitigate known effects of adaptation and loss of efficacy demonstrated in nearly all open-loop continuous deep brain stimulation paradigms. It remains to be seen if similar signals may be non-invasively recorded using electroencephalography to track disease state or inform drug development.

## **Acknowledgements**

We would like to thank Dr. Howard Fields, Dr. Kristin Sellers, and Dr. Julian Motzkin for advice during study design and data analysis and for critical editing of the manuscript. This study was funded by NIH Brain Initiative Grant UH3 NS109556 (E.F.C., P. Shirvalkar and P. Starr) NIH HEAL Initiative Grant UH3NS115631 (Shirvalkar) and DARPA grant W911NF-14-2-0043 (E.F.C.). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

## **Author Contributions Statement**

P. Shirvalkar, P. Starr, and EFC conceptualized and designed the study and acquired funding. P. Shirvalkar GC, MD, and AS collected all data and maintained data integrity. P. Shirvalkar, JP, GC, PA, and OS had full access to all the data and performed formal analysis. MMS supervised the state-space modeling of data. P. Shirvalkar drafted the manuscript. All authors participated substantially in the critical revision of the manuscript for intellectual

content. HD performed project administration. Study supervision was conducted by P. Starr and EFC.

## **Competing Interests Statement**

Medtronic Inc. provided research devices for use in this study, and technical support through a research agreement with UCSF (with E.F.C. and P. Shirvalkar), but no financial support. Medtronic Inc. had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. All authors have no other conflicts of interest to report.

**Tables** NONE

## Methods

### General Trial Methods

This current study was undertaken as part of ongoing multi-year clinical trial aimed at developing closed loop control algorithms for deep brain stimulation to treat chronic neuropathic pain. The clinical trial protocol (NCT03029884 found at [www.clinicaltrials.gov](http://www.clinicaltrials.gov)) was approved by UCSF Human Research Protection Program (IRB) and the Food and Drug Administration (FDA).

Inclusion and exclusion criteria are as follows:

#### Inclusion Criteria:

- Age  $\geq$  21 years
- Clinical diagnosis of post-stroke pain (thalamic pain), spinal cord injury or phantom limb pain with allodynia or dysesthesia with pinprick anesthesia or hypoesthesia on the affected hemi-body or limb (anesthesia dolorosa).
- For Post-Stroke Pain: Stroke of ischemic etiology only. MRI done within one year of surgery showing a lesion that involves the contralateral brainstem, thalamus, or cortex. The lesion will involve cortical-subcortical areas in topography consistent with sensory thalamocortical connections. This will include patients with infarcts in the territory of the middle cerebral artery. A more recent MRI may be required if the patient's condition changed within the previous year.
- For Phantom limb pain: MRI done within one year not showing any contraindication to surgery such as mass, lesion, hemorrhage, or other abnormality near target
- For Spinal Cord Injury pain: MRI done within one year not showing contraindication to surgery such as mass, lesion, hemorrhage, or other abnormality near target
- One year or more of medically refractory severe pain (see below)
- Average daily pain for the past 30 days reported as  $>5$  on a 0-10 numeric rating scale (NRS)
- Failure to respond adequately to at least one antidepressant, one anti-seizure medication and one oral narcotic with current stable doses of medications.
- Ability to speak / read English
- Capable of understanding and providing informed consent
- Stable doses of pain medications (e.g., anticonvulsant drug, anti-depressants, and opioids etc.) for at least 30 days
- Women of childbearing age must be on regular use of an accepted contraceptive method(s).

#### Exclusion Criteria:

- Pregnancy or breast feeding
- Inability to speak and / or read English
- Inability to give informed consent
- Significant cognitive impairment or dementia (MoCA  $<$  25)
- Aphasia severe enough to limit the consent process or communication between the investigators and the patient. Patients with mild or recovering aphasia may be considered candidates at the discretion of the PI.
- Recommendation of exclusion by evaluating psychiatrist based on comprehensive neuropsychological evaluation which may include the following conditions: Active depression (BDI  $>$  20) or other untreated or uncontrolled psychiatric illness (active general anxiety disorder, schizophrenia, bipolar disorder, obsessive-compulsive disorder (OCD), or personality disorders (e.g., multiple personality disorder, borderline personality disorder, etc.)
- Suicide attempt within the prior 12 months or imminent suicide risk
- History of substance abuse in the prior 3 years.
- Major medical co-morbidities increasing the risk of surgery including uncontrolled hypertension, severe diabetes, major organ system failure, history of hemorrhagic stroke, need for chronic anticoagulation other than aspirin, active infection, immunocompromised state or malignancy with  $<$  5 years life expectancy
- Inability to stop Coumadin or platelet anti-aggregation therapy for surgery and after surgery. Patients taking these medications will need to discuss the need/risk of continuing these medications with their physicians and the PI or study personnel may contact the treating physician(s) as well to discuss the risks of anticoagulation / antiaggregation therapy discontinuation.
- Coagulopathy. Patients will be excluded unless assessed and cleared by hematology.
- MRI (done within one year of surgery) with significant abnormalities other than those associated with the neurological disorder causing chronic pain.
- Implantable hardware not compatible with MRI or with the study.
- Inability to comply with study follow-up visits
- Previous ablative intracranial surgery for the management of thalamic pain syndrome.
- Previously implanted with deep brain stimulation system or any previously implanted device treatment involving brain stimulation

- Major neurological disorder other than the one that led to the chronic pain including epilepsy, neurodegenerative condition or any history of seizure
- Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) to treat a chronic condition
- Has an implanted electronic device such as a neurostimulator, cardiac pacemaker or medication pump
- Allergies or known hypersensitivity to materials in the Activa PC+S system (i.e., titanium, polyurethane, silicone, polyetherimide, stainless steel).
- Pregnancy or lack of regular use of contraceptives. Patients who become pregnant after enrollment may be excluded from the study. Patients who become pregnant prior to the surgical implantation of the DBS systems will be excluded from the study.
- Patients may be excluded from enrollment due to a condition that, in the judgment of the PI, significantly increases risk or reduces significantly the likelihood of benefit from brain stimulation.

### Participants

Four right-handed participants (CP1-4) with refractory neuropathic pain limited to one side of the body for >1 year were enrolled in an ongoing study to devise adaptive brain stimulation for pain. Three participants had post-stroke pain and one had phantom limb pain (**Figure 1A, Table S1**). Half were women and the mean ( $\pm$ SD) age was  $58.5\pm 3.1$  years; all were free from untreated depression, recent substance use disorder and cognitive impairment. All participants maintained constant doses of medications for three months. Each participant signed written informed consent and the study was approved by both FDA under an Investigational Device Exemption and UCSF Committee on Human Research. Participants were reimbursed for travel and accommodations, but not otherwise compensated.

### *Brief Patient Descriptions*

(see **Table S3** for task related temperature calibration quantitatively reflecting allodynia)

**CP1:** 58-year-old woman with a history of central post-stroke pain syndrome (CPSP), after right middle cerebral artery infarct in 2013. Approximately 12 weeks after her stroke, she began having sharp, burning, stabbing pain in the left hemi-body from her head to foot, most severely concentrated over the left hand/ arm and leg. Pain focused neurological

exam was notable for hemiparesis in the left arm and leg, with reduced sensation to light touch and temperature along the whole left arm, ankle and foot. She experienced dynamic mechanical, cold and heat allodynia with symptoms of hyperpathia involving the spatial spread of lingering pain in response to rapidly repeated stimuli (interval <3 seconds).

**CP2:** 63-year-old woman with elective right leg above-the-knee amputation in 2016 (for pain) and refractory phantom limb pain with right leg, calf and foot pain involving burning and pressure sensation. Her leg pain began 4.5 years prior to enrollment resulting from compartment syndrome as a complication from total knee arthroplasty. Pain focused neurological exam was normal, with no stump pain nor evoked sensations on palpation of the stump (Negative Tinel's sign). She did not have sensory loss, weakness or allodynia.

**CP3:** 56-year-old man with history of hypertension and left thalamic infarct in 2014, with persistent CPSP involving the right sided face, arm and leg. Beginning 5 days post stroke, he developed severe burning pain associated with dysesthesias of the right bicep, forearm and leg. Pain focused neurological exam showed intact motor and sensory function with notable hyperalgesia and allodynia in the right arm and leg. Allodynia was confined to cold and heat allodynia, with minimal mechanical allodynia.

**CP4 -** 59 year old man with history of prostate cancer (no current disease), solitary episode of atrial fibrillation and CPSP after left posterior cerebral artery infarct in April 2017. Approximately six weeks after his stroke, he began having burning and stabbing pain in the right arm as well as the right ankle which progressed to involve the entire right hemi-body after 1 year. Pain focused neurological exam was notable for mild hemiparesis in the right arm, with intact sensation to light touch and temperature all over. There was dynamic mechanical, cold and heat allodynia in the right arm (worst distal to the elbow circumferentially) and leg (worst below mid calf on the right including whole ankle and foot).

### Device implant surgery

All participants underwent chronic intracranial electrode and neurostimulator implant targeting ACC and OFC using Medtronic electrodes connected to the Activa PC+S device<sup>26</sup> (bilateral in three participants, unilateral in CP1 contralateral to side of pain). Multi-electrode leads targeted dorsal anterior cingulate cortex (models 3389/3387) and

subdural surface of orbitofrontal cortex (paddle# 3587A/0930A) using frame-based stereotaxy under general anesthesia. Individual trajectories were determined using neurosurgical mapping software from BrainLab Inc. and Medtronic Stealth 8.0 based on preoperative 3T MRI scans (**Figure S1**).

For dorsal anterior cingulate cortex (ACC), target locations for each electrode tip were determined by computing diffusion tractography images (DTI, 55 directions) and identifying the cingulum bundle in a region 20-25mm posterior to the anterior border of the lateral ventricle (Supplementary Figure 1, Supplementary Methods) as in a prior study<sup>34</sup>. For orbitofrontal cortex (OFC), a burr hole was made through the temporal bone to allow passage of the paddle lead to the subdural surface. Note that we targeted both medial and lateral OFC, areas that overlap with definitions of the ventrolateral medial prefrontal cortex in other studies. Electrodes were advanced through frontal burr holes, with correct placement confirmed by intraoperative CT and re-confirmed by CT at the 2-month visit. Stim-loc devices were used for electrode lead anchoring, with a strain relief loop anterior to the site of anchoring to prevent movement or torque on the lead over time. The free ends of the leads were then placed in a subgaleal pocket, created by blunt dissection in the parietal area. A lead extender was tunneled subcutaneously between the parietal incision and a 5 cm incision over the pectoralis muscle, where a pocket was bluntly dissected for the Activa implantable neurostimulator (INS) system. A small amount of Medtronic medical glue was applied to the junction of the lead and each barrel of the INS to mitigate electrical cardiac artifact. Participants had at least 10 days of recovery before neural data collection began.

### **Electrode Localization and Brain Imaging**

Electrode (depth and paddle ECoG) contact locations were reconstructed using a CT scan taken 2-3 months after implantation and fused with the preoperative T1-weighted volumetric MRI. The T1 MRI was used to construct cortical surface models in FreeSurfer version 7.1.1<sup>47,48</sup>. We projected ECoG contacts onto the cortical surface mesh with the `imgpipe` toolbox<sup>49</sup> using a surface vector projection method<sup>50</sup>. Once we identified locations for each ECoG and depth electrode, we projected all patients' electrodes onto Montreal Neurological Institute 152 space for plotting and comparison.

In addition to the stereotactic preoperative MRI scans, High Angular Resolution Diffusion Imaging (HARDI) was acquired on the same 3 Tesla

MR scanner (General Electric, Inc.), using a spin-echo echo-planar imaging (SE EPI) pulse sequence (TE = 71 ms, TR = 7765 ms, flip angle  $\alpha = 90^\circ$ ), FOV 28x28cm, at least 70 axial slices, 2 mm<sup>3</sup> isotropic voxels,  $b$ -value = 2000 s mm<sup>-2</sup> in 55 non-collinear gradient directions and a signal to noise ratio >60. A single non-diffusion-weighted  $b_0$  image was also obtained. The diffusion-weighted tractography was processed using BrainLab software (Feldkirchen, Germany). Preoperative MRI, postoperative CT and HARDI scans were automatically merged and corrected for distortion. The contacts used for recordings were segmented on the CT scan based on visible contacts and known spacing measurements. The regions of interest (ROIs) were created using manual tracing of bilateral dorsal anterior cingulate cortex, using a fractional anisotropy threshold between 0.2-0.3 and a minimum length of at least 8cm.

### **Ambulatory data collection**

We collected neural recordings coincident with pain reports multiple times daily (mean 3.5 per day) from morning to evening. The Activa PC+S system is an investigational, implantable "bidirectional" neural interface, that can sense and store patient triggered neural recordings (LFP time series) that can be analyzed offline or used for adaptive DBS.<sup>26</sup> Participants initiated a 30-second neural recording using their remote control while sitting quietly, immediately following a pain report. Each 30 second neural recording was self-triggered by participants by pressing a button on their remote control. Participants were instructed to space out recordings at least three times daily, once each in the morning, afternoon, and evening. In rare instances (< 10% of all recordings), devices were programmed to automatically capture a 30 second recording at prespecified times throughout the day, to increase recording frequency. In such cases, we attempt to vary specific times of recordings every 2 weeks to more equally sample morning, afternoon, and evening periods. Also, in these cases participants were notified of the imminent start of a recording via text message and prompted to submit a pain report via text message or by clicking a hyperlink to a Redcap survey page. Neural recordings were included in analysis only if they occurred within 15 minutes of reported scores.

Pain metrics were reported using mobile text message or the online Redcap platform version 10.0.33 (Redcap, Vanderbilt Inc.). Reported metrics included pain intensity numerical rating score (NRS, 0-10) and visual analog scale (VAS where 0 is no

pain and 10 is the worst pain they have ever experienced); pain unpleasantness NRS and VAS (where 0 is not bothersome at all and 10 is most bothersome ever felt), and the short form McGill Pain Questionnaire version 2 (SF-MPQ).<sup>28</sup> Although VAS and NRS may provide redundant information, both were collected when possible to assess reporting consistency within-participant (**Figure 1C**). While data from all metrics were not available from all participants, pain intensity NRS was reported by all and so prioritized in the study.

Participants provided pain reports at least 2 weeks prior to surgery, and reported score means did not change after surgery. To standardize reporting, participants were trained to report pain intensity NRS values based on a narrative description of each number (0-10) from a comparative pain severity scale table.<sup>51</sup> VAS sliders contained only the numbers 0 or 10 at each end and were presented horizontally with the slider bar starting at a value of 5/10. The short-form McGill pain questionnaire version 2 is a multidimensional survey tool that requires participants to rate the extent (none, mild, moderate, severe) to which each of 15 pain words matches their symptoms. We reported the SF-MPQ2 score as the sum of all verbal descriptor ratings (maximum = 45). The magnitude by which pain scores differ between the high and low group within each patient was confirmed to be clinically significant and surpasses a meaningful threshold for each participant. All patients confirmed that individual successive numbers in reported ranges carried discernable clinical meaning, and so a NRS difference of 1 out of 10 was therefore noted separately by each participant to have different clinical meaning with reliability over repeated reports (see **Figure 1D**). Brain recordings commenced immediately after pain reports were submitted.

#### **Activa PC+S neural recordings and preprocessing**

Each recording sampled two bipolar referenced time series channels capturing local field potentials (LFP) at 422 Hz sampling rate. The contacts used for sampling were chosen based on those showing the largest root mean square voltage in the raw tracings as determined by investigators (e.g., for ACC we chose 0-3+ as one possible bipolar channel, where 0 was the deepest contact). Data download of collected recordings was performed every 2-3 weeks by either participants or investigators using the Medtronic sensing programmer (ver. 1.5.0.0) via a wand resting on the skin over the Activa device.

Data analysis used MATLAB 2022b (Mathworks, Natick MA) and Python 3.7.4 with the Scikit-learn library, version 1.0.2. To identify pain state biomarkers, local field potentials (LFP) were high-pass filtered above 1 Hz and low-pass filtered below 100 Hz, converted to frequency domain using multitaper spectral estimation,<sup>52</sup> log 10 transformed and z-scored within frequency band. Standardized power values for each 30s recording were averaged within canonical frequency bands:  $\delta$  (1–4 Hz),  $\theta$  (4–8 Hz),  $\alpha$  (8–12 Hz),  $\beta$  (12–30 Hz), low  $\gamma$  (30–70 Hz), and high  $\gamma$  (70–100 Hz). Bandwidths containing idiosyncratic noise sources (known from Activa PC+S by the manufacturer) were visually identified for each participant (by an investigator blinded to results) and excluded from power averages. Outlier recordings were excluded from analysis if power within 3 or more frequency bands (of 6 total) contained power averages greater than 3 scaled median absolute deviations from the median, in a manner blinded to the results.

#### **Acute/Experimental Thermal Pain Protocol**

We applied transient heat stimuli of varying intensity to each participant's most painful body part (and contralateral side) using the Medoc TSA 2001 while recording brain LFP activity. Heat temperatures were calibrated separately for each body side and participant, such that reported NRS values ranged from 0-9 out of 10. Background chronic pain NRS were collected before starting acute pain trials. Participants underwent five trials at each of five intensities, where temperature first increased at a rate of 1 deg C/s from a baseline of 32 deg C, was held at target intensity for 3 seconds, and then returned to baseline. 10 to 15 seconds elapsed between trials, and participants were cued to trial start though 3s of neural data was only included after target temperatures were reached. Target temperatures ranged from 34 to 48 deg C. Participants verbally reported pain NRS 3 seconds after reaching target temperature. Trials with movement or uncertain pain report were discarded.

To mitigate the possibility that participants may "merge" or conflate ratings of chronic and acute pain (even subconsciously), we took 3 precautionary steps: (1) Participants were exposed to at least four different blocks of the acute pain paradigm before formal testing, so that they became accustomed to the pacing and attention to acute, thermal pain phenomenology. (2) Thermal pain was applied adjacent to, instead of directly over, anatomical regions where background chronic pain was experienced, tailored to each participant. This was



done to avoid confounding spontaneous underlying pain in the same body part that was in physical contact with the thermode. (3) Participants were explicitly trained to provide only the pain score corresponding in time (by verbal cueing at the 3 second plateau timepoint) and in space (in only the anatomical area contacted by the thermode). To specifically train patients to understand this difference, they were given visual feedback of the temperature as it ramped to target temperature during training blocks, so that they could understand the relationship between stimulus delivery and perceived sensation. However, to avoid bias, they were not shown the visual temperature during actual testing blocks.

### **Pain Decoding Models and Biomarker Analysis**

Separate models were constructed for each participant and each reported pain score, using as input features the standardized mean spectral power in each frequency band, per brain region, per hemisphere (i.e., CP1 model used 12 features (6 each from unilateral implants in ACC and OFC); CP2-4 models contained 24 features from bihemispheric recordings). We computed multivariate regularized regression (LASSO) on continuous pain metrics and two types of classification on dichotomized pain metrics (LDA and LSSM). For classification, binary response variables were pain scores dichotomized into “high pain state” and “low pain state” categories for each participant, based on dividing scores above and below that participant’s median value (test data point was not included in median calculation for full independence, see *Cross Validation* method). To ensure robust decoding of pain state, we used independent machine learning approaches: Linear Discriminant Analysis (LDA), Linear State Space Modeling (LSSM, **Figure S2**) and LASSO regression. While LDA produces directly interpretable feature weights which can be programmed into currently available adaptive DBS devices, LSSM is a dynamical systems approach that can more flexibly represent complex brain activity.<sup>53</sup>

The approaches below were used to predict multiple pain metric responses that were available for each participant (see **Table S1**): All participants: chronic pain intensity NRS, acute pain verbal NRS, acute pain temperature; CP3 and CP4: pain intensity VAS, pain unpleasantness NRS/ VAS, McGill Pain Questionnaire- Short Form version 2.

1- Least Absolute Shrinkage and Selection Operator (LASSO) regression: In addition to predicting binarized chronic and acute pain states, we also trained multivariate LASSO regression models to predict continuous pain scores. LASSO regression models implicitly perform variable selection through regularization whereby the weighting factors of multicollinear or extraneous input variables are shrunk, thereby having less influence on the outcome prediction. Similar to LDA models, we stratified our regression analyses by constructing models trained on data separately from each available subregion. All models were fit with a regularization parameter of 0.001 and validated with our modified LOOCV. Model fit was evaluated by calculating the coefficient of determination ( $R^2$ ) values of the models, which can range from below 0 to 1, and root mean squared error (RMSE).

2- Linear Discriminant Analysis (LDA) decoding: Linear discriminant analysis is a common supervised classification method used to categorize labeled samples into two or more classes by determining an optimal decision boundary that best separates samples from each class<sup>54</sup>. LDA makes predictions by estimating the probability that each input belongs to a particular class based on variance in the input features.

We used LDA to classify high vs low dichotomized pain states for two main reasons. First, LDA produces an interpretable set of feature weights for each trained model, permitting inference of the importance of specific neural features (i.e. brain regions, hemisphere, power bands)<sup>54</sup>. Second, the Activa PC+S, Summit RC+S and Percept sensing-enabled brain stimulation devices (Medtronic Inc.) exclusively use device-embedded LDA algorithms for ambulatory closed-loop control<sup>55,56</sup>. Results from LDA based decoding can therefore be directly implemented for closed-loop control in current clinical devices and for future stimulation studies.

We constructed multiple LDA classification models using data sub-selected from different brain regions and/or hemispheres, which we called *subregion models* (e.g., right hemisphere ACC and OFC, left ACC, left OFC, etc.). One model consisting of all available data (e.g., both hemispheres and brain regions) was termed the *full model* (i.e., Contralateral ACC/OFC for CP1 and Bilateral ACC/OFC for CP2-4 represent the *full model*). Separate *full and subregion models* were constructed to classify each available pain metric per participant (i.e. pain intensity numerical rating

score (NRS) and visual analog scale (VAS), pain unpleasantness NRS and VAS, and short-form McGill Pain Questionnaire version 2 (SF-MPQ)<sup>28</sup>). However, pain intensity NRS was reported by all participants and so is emphasized in the main study. For the acute pain data, we also sought to predict the delivered temperature as a response variable. For all participants, we optimized the shrinkage parameter used for discriminant analysis, which was set to the default value for all participants except for CP1 for whom it was set to a value of 1, indicating maximum shrinkage. Shrinkage is a form of regularization used to improve model estimation in scenarios when the number of training samples is low relative to input features<sup>57</sup>. Setting shrinkage to a value of 1 effectively maximizes regularization. All other hyperparameters were set to default values (e.g. prior probabilities = 0.5 for each class) in Python 3.7.4 with the Scikit-learn library, version 1.0.2<sup>57</sup>.

Area under the curve (AUC) was calculated using the predictions from all test points compared to the ground truth pain states for all models. We also calculated sensitivity, specificity, positive predictive value, and accuracy of binary classification.

To determine whether neural features correlated with chronic pain may generalize to acute (experimental) pain, we used *full models* trained on the chronic pain dataset to classify acute pain scores from the experimental thermal pain dataset, and vice versa (**see Figure 4A**). Specifically, for this acute/chronic generalization analysis, a particular participant's neural features and pain reports from the chronic pain dataset were used as the training set, while that same participant's neural features and pain reports from the acute, experimental thermal pain dataset were used as the test set. The same analysis was done by reversing the test and training sets for completeness. Neural input features and pain score response variables were standardized by subtracting the mean and dividing by standard deviation for each model.

3- Linear State Space Model (LSSM) decoding: Neural decoding of pain may benefit from dynamic models that can predict how neural dynamics lead to pain score variations over time. Such an approach was previously used to decode interindividual mood state in epilepsy patients and can reduce the dimensionality of neural features to fewer 'latent states' which can then be used to guide stimulation in a potential future control scheme (**Figure S2**). We thus independently assessed the feasibility of

decoding chronic pain state using dynamic linear state space models (LSSM)<sup>53</sup>.

In this case, in non-overlapping 1s windows, we computed log of signal power within the 6 canonical frequency bands (see Methods) resulting in power timeseries with 30 time-steps during each 30s recording. We modeled the dynamics of the power timeseries as the outputs of an LSSM with a latent state and used the subspace identification algorithm and Akaike's information criterion to learn the LSSM parameters and determine its latent state dimension<sup>53</sup>. Given the learned LSSM, we then applied the associated Kalman filter to the power timeseries in each recording to extract the latent state timeseries and decoded the pain state from the latent state at the end of each recording. Decoding was evaluated as above with a modified LOOCV and performance was quantified by computing the AUC. As LSSM methods may predict neural dynamics over time, they could hold promise for informing closed-loop adaptive DBS system<sup>58</sup>, though present technology relies on LDA approaches<sup>26,46</sup>.

### Cross-Validation

To mitigate model overfitting, we used leave-one-out cross-validation (LOOCV) in which one test sample was iteratively omitted from the training set (see Table S1 for number of recordings for each participant). Specifically, for all models, we predicted each test data point individually using a model trained on all other points. For all models, the median value used for dichotomizing pain scores was computed using only the training dataset (excluding the test data sample) to maintain strict independence between training and testing sets. Decoding AUCs were averaged across all runs to compute the model average AUC reported in the text and figures.

It is possible that autocorrelations in the pain score metric timeseries could result in potentially overfitted models and inflate prediction accuracy. Therefore, we performed a separate 'modified cross validation' procedure which omitted  $\pm 3$  samples around the test point, from the training data. We chose a window of 3 samples based on the average number of pain scores reported per day across participants (3.2 reports/day). For participants CP2-4, the 'modified cross validation' method resulted in significant decoding of pain intensity NRS for all *subregion models* containing the ACC or OFC from the contralateral hemisphere (6 of 9 models per participant). For the one participant with the smallest number of data samples (CP1), this method failed to produce significant classification of pain intensity

NRS, due to the omission of substantially more training data than the standard LOOCV method. Consistent with shown results for the two participants with pain unpleasantness NRS reporting, the 'modified cross validation' method resulted in significant decoding when ACC was included in *subregion models* (CP3: 7 of 9 models, CP4: 6 of 9 models). For SF-MPQ II, all subregion models were significant for CP3 and 7 of 9 models were significant for CP4 (excluding those containing ipsilateral OFC).

### Sequential Pain Difference / Pain Fluctuation Analysis

Predicting changes in successive pain scores vs state (**Figures S9a, b**): We were interested in understanding whether the neural features tracked fluctuations or differences between sequential pain ratings (instead of the actual reported individual pain scores/states). Pain score differences were calculated by subtracting the immediately preceding pain score from the current one to generate a metric of whether pain state recently increased or decreased. Therefore, pain scores that were previously higher than the current one would result in negative difference scores, while those that were previously lower would result in positive difference scores. To assess whether neural features discriminated changes in pain, we generated binary LDA classification models trained to distinguish stable (0 change in pain NRS) vs fluctuating pain scores (non-zero changes in pain NRS). We also built regression models trained to predict the change from the prior pain score to the current score. We performed the same *subregion model* stratification and validation methods as described for other models.

**Decoding Stability (70/30 split):** To test whether the important neural features were stable across the ambulatory data collection period, we additionally performed a 70/30 train/test split validation protocol using an LDA classifier. For each patient, we train an LDA model on the first 70% of their collected data and test the model on the remaining 30%. We then calculated the AUC on the test set. If AUC from this analysis is comparable to the AUC computed using modified LOOCV, this suggests that neural features important for decoding are stable over time.

**LDA Feature Importance:** Model feature importance (**Figure 2E, 3G**) was calculated by

taking the mean value of each feature coefficient weight across all cross-validation runs (using LDA) and linearly rescaling the resulting values between -1 and 1 for each feature and participant. The feature importance values were visualized by plotting colored heatmaps ranging from blue to red to compare across participants.

**OFC vs ACC feature comparison:** To further assess the relative contribution of OFC vs ACC features on chronic and acute pain decoding, we computed the difference between the *absolute magnitudes* of each power band feature from OFC and ACC in the same brain hemisphere (OFC minus ACC) for all recording clips. Values greater than 0 indicate greater OFC than ACC feature importance. To compare the distributions of these feature importance differences to a null hypothesis distribution, we generated null permuted distributions by randomly shuffling the OFC/ACC labels and recalculating feature differences 1000 times. Real vs shuffled feature difference distributions were compared using two-tailed Wilcoxon rank sum tests. Multiple comparisons correction was performed across all features within each participant using FDR correction as below.

### Temporal Feature Analysis:

1- To assess the time-varying characteristics of power features supporting pain state decoding, we first computed multitaper spectrograms of neural recordings from each brain region<sup>52</sup>. Spectrograms were computed on 500 msec windows, with 50 msec window step,  $TW = 3$  (1.5 Hz resolution) and 5 tapers, with signals zero padded to the next power of 2 number of samples. We then averaged power values within canonical frequency bands as above (i.e., delta, theta, alpha, etc.) to obtain power timeseries plots for each feature from each brain region. To understand the relative changes in power that underlie decoding of high vs low pain states, we next averaged the feature power timeseries clips belonging to each of the high vs low pain state group (**Figure 5A, S13A**). The same method was carried out for the acute affected pain features for the two participants that had successful acute pain decoding (**Figure S13B**). Note that because the 30s neural recording clips were collected at various times of day within 5 minutes preceding a pain report, there is no well-defined task onset/offset for each 30s recording as there is for each 3s recording clip in the acute pain task. Therefore, one may expect to see reliable increases/ decreases in power if there were sustained power changes across this time.

However, one might not see any difference between low vs high pain power curves if power only fluctuated in transient bursts because the timing of such bursts may cancel out when averaged across sessions.

To quantify increases or decreases in power change patterns for chronic and acute pain features, we computed three metrics (**Figure 5B-D**): (1) *the number of bouts per second*. A bout was defined as an event where the higher power curve crossed above the low power curve before crossing below if at all (e.g., if a feature had a negative feature weight sign, then low pain state was associated with higher power than high pain state for that feature). Instances where the higher power curve did not intersect with the lower power curve were counted as one bout. We divided the number of bouts by clip duration to obtain *bouts per second*. (2) *mean bout duration* was computed by taking an average duration of all detected bouts for that feature. (3) *the total proportion of recording clip time* where the higher curve was sustained above the lower curve (i.e., equivalent to summing all bout durations and dividing by clip duration).

2- To investigate diurnal patterns in the time series of each chronic pain neural feature, we separately plotted pain NRS and each feature's clip averaged power as a function of time of day from midnight to midnight (**Figure S14**). Because the time of day was non-uniformly sampled by each participant in the ambulatory setting, we resampled these diurnal plots with shape-preserving piecewise cubic interpolation ('pchip') using a uniform time resolution of 3 hours to obtain a summary diurnal trend line for each feature. We chose a resolution of 3 hours because this was the shortest time interval across each participant's reports, and because doing so did not introduce visible artifactual trends. The resampled trend lines for each feature were then correlated with the pain NRS trend line using Pearson's correlation, within participant, to assess for correlated patterns between neural features and pain reports (**Table S3**).

### General Statistical Methods

False discovery rate correction for multiple comparisons used the Benjamini-Hochberg-Yekutieli procedure<sup>59</sup>.

Autocorrelation: Sample partial autocorrelations were calculated on reported pain intensity NRS using default parameters in MATLAB<sup>60</sup>. Because pain NRS was reported on an irregular time scale for

each participant, we uniformly resampled the original pain NRS timeseries using shape-preserving piecewise cubic interpolation, rounded to the nearest 6 minutes (i.e., 1/10 of 1 hour).

Permutation Tests: Empirical p-values: All machine learning model results (AUCs for LDA and LSSM and Coefficient of determination  $R^2$  for regression) were compared against 5000 (n) permuted results from null models (AUCs or  $R^2$ ) obtained by randomly shuffling the true response class labels or values (e.g., randomly shuffling high or low pain class label) to obtain a distribution of chance level performance. We conservatively calculated empirical one-sided p-values by comparing the number of randomly permuted AUCs or  $R^2(k)$  greater than the actual model AUC or  $R^2$  using the following correction to avoid underestimation as previously demonstrated<sup>61</sup>:  $p^{corr} = k+1 / n+1$ . Note that because  $R^2$  values can be  $< 0$ , it is possible for very low  $R^2$  values to sometimes be significant, if the  $R^2$  results from shuffled / permuted, null models were largely negative.

### Data availability Statement

The datasets generated during and/or analyzed during the current study will be available in the NIH Brain initiative data sharing platform within one month of publication at the following link (<https://dabi.loni.usc.edu/>). Data sets will include raw neurophysiology data including metadata.

### Code Availability Statement

MATLAB and Python analytical software code used to generate the main results and figures is available on the NIH Brain Initiative platform above and at Github at the following address: [https://github.com/shirvalkarlab/ChronicPain2023\\_NatNeuro.git](https://github.com/shirvalkarlab/ChronicPain2023_NatNeuro.git)

### References

1. CDC. *Wide-ranging online data for epidemiologic research (WONDER)*. vol. 2016 (2016).
2. FDA-NIH Biomarker Working Group. *BEST (Biomarkers, EndpointS, and other Tools) Resource*. (Food and Drug Administration (US), 2016).
3. Davis, K. D. *et al*. Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and

- opportunities. *Nature Reviews Neurology* **16**, 381–400 (2020).
4. Coghill, R. C., McHaffie, J. G. & Yen, Y.-F. Neural correlates of interindividual differences in the subjective experience of pain. *PNAS* **100**, 8538–8542 (2003).
  5. Hutchison, W. D., Davis, K. D., Lozano, A. M., R. R. Tasker & Dostrovsky, J. O. Pain-related neurons in the human cingulate cortex. *Nature Neuroscience* **2**, 403–405 (1999).
  6. Wager, T. D. *et al.* An fMRI-Based Neurologic Signature of Physical Pain. *New England Journal of Medicine* **368**, 1388–1397 (2013).
  7. Ploner, M., Sorg, C. & Gross, J. Brain Rhythms of Pain. *Trends in Cognitive Sciences* **21**, 100–110 (2017).
  8. Baliki, M. N. *et al.* Chronic Pain and the Emotional Brain: Specific Brain Activity Associated with Spontaneous Fluctuations of Intensity of Chronic Back Pain. *Journal of Neuroscience* **26**, 12165–12173 (2006).
  9. Baliki, M. N. *et al.* Corticostriatal functional connectivity predicts transition to chronic back pain. *Nature Neuroscience* **15**, 1117–1119 (2012).
  10. Corder, G. *et al.* An amygdalar neural ensemble that encodes the unpleasantness of pain. *Science* **363**, 276–281 (2019).
  11. Tan, L. L. *et al.* A pathway from midcingulate cortex to posterior insula gates nociceptive hypersensitivity. *Nat Neurosci* **20**, 1591–1601 (2017).
  12. Lee, J.-J. *et al.* A neuroimaging biomarker for sustained experimental and clinical pain. *Nature Medicine* 1–9 (2021) doi:10.1038/s41591-020-1142-7.
  13. Lee, M. *et al.* Activation of Corticostriatal Circuitry Relieves Chronic Neuropathic Pain. *J. Neurosci.* **35**, 5247–5259 (2015).
  14. Rainville, P., Duncan, G. H., Price, D. D., Carrier, B. & Bushnell, M. C. Pain Affect Encoded in Human Anterior Cingulate But Not Somatosensory Cortex. *Science* **277**, 968–971 (1997).
  15. Boccard, S. G. J. *et al.* Long-Term Results of Deep Brain Stimulation of the Anterior Cingulate Cortex for Neuropathic Pain. *World Neurosurgery* **106**, 625–637 (2017).
  16. Kringelbach, M. L. & Rolls, E. T. The functional neuroanatomy of the human orbitofrontal cortex: evidence from neuroimaging and neuropsychology. *Progress in Neurobiology* **72**, 341–372 (2004).
  17. Kucyi, A. & Davis, K. D. The dynamic pain connectome. *Trends in Neurosciences* **38**, 86–95 (2015).
  18. Kringelbach, M. L. The human orbitofrontal cortex: linking reward to hedonic experience. *Nat Rev Neurosci* **6**, 691–702 (2005).
  19. Damasio, A. R. The somatic marker hypothesis and the possible functions of the prefrontal cortex. *Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences* (1996) doi:10.1098/rstb.1996.0125.
  20. Becker, S., Gandhi, W., Pomares, F., Wager, T. D. & Schweinhardt, P. Orbitofrontal cortex mediates pain inhibition by monetary reward. *Soc Cogn Affect Neurosci* **12**, 651–661 (2017).
  21. Rich, E. L. & Wallis, J. D. Decoding subjective decisions from orbitofrontal cortex. *Nature Neuroscience* **19**, 973–980 (2016).
  22. Rao, V. R. *et al.* Direct Electrical Stimulation of Lateral Orbitofrontal Cortex Acutely Improves Mood in Individuals with Symptoms of Depression. *Current Biology* **28**, 3893-3902.e4 (2018).
  23. Kohoutová, L. *et al.* Individual variability in brain representations of pain. *Nat Neurosci* **25**, 749–759 (2022).
  24. Čeko, M., Kragel, P. A., Woo, C.-W., López-Solà, M. & Wager, T. D. Common and stimulus-type-specific brain representations of negative affect. *Nat Neurosci* **25**, 760–770 (2022).
  25. Petrovic, P., Kalso, E., Petersson, K. M. & Ingvar, M. Placebo and Opioid Analgesia--Imaging a Shared Neuronal Network. *Science* **295**, 1737–1740 (2002).
  26. Swann, N. C. *et al.* Chronic multisite brain recordings from a totally implantable bidirectional neural interface: experience in 5 patients with Parkinson's disease. *Journal of Neurosurgery* **128**, 605–616 (2017).
  27. Giordano, J. J. *et al.* Proceedings of the Fourth Annual Deep Brain Stimulation Think Tank: A Review of Emerging Issues and Technologies. *Front Integr Neurosci* **10**, 38 (2016).
  28. Strand, L. I., Ljunggren, A. E., Bogen, B., Ask, T. & Johnsen, T. B. The Short-Form McGill Pain Questionnaire as an outcome measure: Test–retest reliability and responsiveness to change. *European Journal of Pain* **12**, 917–925 (2008).
  29. Hawker, G. A., Mian, S., Kendzerska, T. & French, M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain

- Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). *Arthritis Care & Research* **63**, S240–S252 (2011).
30. Salgado, J. F. Transforming the Area under the Normal Curve (AUC) into Cohen's d, Pearson's rpb, Odds-Ratio, and Natural Log Odds-Ratio: Two Conversion Tables. *Psy. intervention* **10**, 35–47 (2018).
  31. Tracey, I. & Mantyh, P. W. The Cerebral Signature for Pain Perception and Its Modulation. *Neuron* **55**, 377–391 (2007).
  32. Hashmi, J. A. *et al.* Shape shifting pain: chronification of back pain shifts brain representation from nociceptive to emotional circuits. *Brain* **136**, 2751–2768 (2013).
  33. Reckziegel, D. *et al.* Deconstructing biomarkers for chronic pain: context- and hypothesis-dependent biomarker types in relation to chronic pain. *PAIN* **160**, S37 (2019).
  34. Boccard, S. G. J. *et al.* Targeting the Affective Component of Chronic Pain: A Case Series of Deep Brain Stimulation of the Anterior Cingulate Cortex. *Neurosurgery* **74**, 628–637 (2014).
  35. Kulkarni, B. *et al.* Attention to pain localization and unpleasantness discriminates the functions of the medial and lateral pain systems. *Eur J Neurosci* **21**, 3133–3142 (2005).
  36. Derbyshire, S. W. G. *et al.* Cerebral responses to noxious thermal stimulation in chronic low back pain patients and normal controls. *Neuroimage* **16**, 158–168 (2002).
  37. Shih, H.-C., Yang, J.-W., Lee, C.-M. & Shyu, B.-C. Spontaneous Cingulate High-Current Spikes Signal Normal and Pathological Pain States. *J Neurosci* **39**, 5128–5142 (2019).
  38. Brodersen, K. H. *et al.* Decoding the perception of pain from fMRI using multivariate pattern analysis. *NeuroImage* **63**, 1162–1170 (2012).
  39. Fries, P. Rhythms for Cognition: Communication through Coherence. *Neuron* **88**, 220–235 (2015).
  40. Colgin, L. L. *et al.* Frequency of gamma oscillations routes flow of information in the hippocampus. *Nature* **462**, 353–357 (2009).
  41. Wang, X.-J. Neurophysiological and Computational Principles of Cortical Rhythms in Cognition. *Physiological Reviews* (2010) doi:10.1152/physrev.00035.2008.
  42. Ede, F. van, Quinn, A. J., Woolrich, M. W. & Nobre, A. C. Neural Oscillations: Sustained Rhythms or Transient Burst-Events? *Trends in Neurosciences* **41**, 415–417 (2018).
  43. Feingold, J., Gibson, D. J., DePasquale, B. & Graybiel, A. M. Bursts of beta oscillation differentiate postperformance activity in the striatum and motor cortex of monkeys performing movement tasks. *PNAS* **112**, 13687–13692 (2015).
  44. Foss, J. M., Apkarian, A. V. & Chialvo, D. R. Dynamics of Pain: Fractal Dimension of Temporal Variability of Spontaneous Pain Differentiates Between Pain States. *Journal of Neurophysiology* **95**, 730–736 (2006).
  45. Rothaug, J., Weiss, T. & Meissner, W. How Simple Can it Get? Measuring Pain With NRS Items or Binary Items. *The Clinical Journal of Pain* **29**, 224–232 (2013).
  46. Gilron, R. *et al.* Long-term wireless streaming of neural recordings for circuit discovery and adaptive stimulation in individuals with Parkinson's disease. *Nat Biotechnol* 1–8 (2021) doi:10.1038/s41587-021-00897-5.
  47. Dale, A. M., Fischl, B. & Sereno, M. I. Cortical Surface-Based Analysis: I. Segmentation and Surface Reconstruction. *NeuroImage* **9**, 179–194 (1999).
  48. Fischl, B. *et al.* Whole Brain Segmentation: Automated Labeling of Neuroanatomical Structures in the Human Brain. *Neuron* **33**, 341–355 (2002).
  49. Hamilton, L. S., Chang, D. L., Lee, M. B. & Chang, E. F. Semi-automated Anatomical Labeling and Inter-subject Warping of High-Density Intracranial Recording Electrodes in Electrocorticography. *Front. Neuroinform.* **11**, (2017).
  50. Kubanek, J. & Schalk, G. NeuralAct: A Tool to Visualize Electrocortical (ECoG) Activity on a Three-Dimensional Model of the Cortex. *Neuroinform* **13**, 167–174 (2015).
  51. Rich, Alice. Comparative Pain Scale. [https://clusterheadachewarriors.org/wp-content/uploads/2017/03/0-10\\_Pain\\_Scale.pdf](https://clusterheadachewarriors.org/wp-content/uploads/2017/03/0-10_Pain_Scale.pdf) (2014).
  52. Bokil, H., Andrews, P., Kulkarni, J. E., Mehta, S. & Mitra, P. Chronux: A Platform for Analyzing Neural Signals. *J Neurosci Methods* **192**, 146–151 (2010).
  53. Sani, O. G. *et al.* Mood variations decoded from multi-site intracranial human brain activity. *Nature Biotechnology* **36**, 954–961 (2018).
  54. Bishop, C. *Pattern Recognition and Machine Learning*. (Springer-Verlag, 2006).



55. Stanslaski, S. *et al.* Design and Validation of a Fully Implantable, Chronic, Closed-Loop Neuromodulation Device With Concurrent Sensing and Stimulation. *IEEE Transactions on Neural Systems and Rehabilitation Engineering* **20**, 410–421 (2012).
56. Afshar, P. *et al.* A translational platform for prototyping closed-loop neuromodulation systems. *Front. Neural Circuits* **6**, (2013).
57. Pedregosa, F. *et al.* Scikit-learn: Machine Learning in Python. *MACHINE LEARNING IN PYTHON* **6**.
58. Shanechi, M. M. Brain–machine interfaces from motor to mood. *Nature Neuroscience* **22**, 1554–1564 (2019).
59. Yekutieli, D. & Benjamini, Y. Resampling-based false discovery rate controlling multiple test procedures for correlated test statistics. *Journal of Statistical Planning and Inference* **82**, 171–196 (1999).
60. Box, G. E. P., Jenkins, G. M. & Reinsel., G. C. *Time Series Analysis: Forecasting and Control*. (Prentice Hall, 1994).
61. North, B. V., Curtis, D. & Sham, P. C. A Note on the Calculation of Empirical P Values from Monte Carlo Procedures. *Am J Hum Genet* **71**, 439–441 (2002).